GSK and CureVac Revise mRNA Vaccine Collaboration Agreement, Granting GSK Full Rights to Influenza and COVID-19 Candidates

GSK and CureVac Redraft mRNA Vaccine Collaboration Agreement in New Licensing Deal, Granting GSK Full Rights to Develop Flu and COVID-19 Candidate Vaccines (Including Combination Vaccines). CureVac to Receive €400 Million Upfront Payment and Up to €1.05 Billion in Milestones and Royalties. CureVac Retains Exclusive Rights to Undisclosed and Preclinically Validated Additional Infectious Disease Targets from Previous Collaboration, Along with Freedom to Independently or Collaboratively Develop mRNA Vaccines in Any Other Infectious Disease or Indication Areas. CureVac’s Ongoing Patent Litigation Against Pfizer/BioNTech Remains Unaffected by the New Agreement. (Jiemian)Original link